A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy
Clinical trial NCT04150575 · UNKNOWN
Trial details
- NCT number
- NCT04150575
- Sponsor
- Shanghai Henlius Biotech
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-10
- Primary completion
- 2022-06-15
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.